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Abstract
Objectives To quantify the relationship between exposure
to lacosamide monotherapy and seizure probability, and to
simulate the effect of changing the dose regimen.
Methods Structural time-to-event models for dropouts (not
because of a lack of efficacy) and seizures were developed
using data from 883 adult patients newly diagnosed with
epilepsy and experiencing focal or generalized tonic–clonic
seizures, participating in a trial (SP0993; ClinicalTrials.gov
identifier: NCT01243177) comparing the efficacy of laco-
samide and carbamazepine controlled-release monother-
apy. Lacosamide dropout and seizure models were used for
simulating the effect of changing the initial target dose on
seizure freedom.
Results Repeated time-to-seizure data were described by a
Weibull distribution with parameters estimated separately
for the first and subsequent seizures. Daily area under the
plasma concentration–time curve was related linearly to the
log-hazard. Disease severity, expressed as the number of
seizures during the 3 months before the trial (baseline),
was a strong predictor of seizure probability: patients with
7–50 seizures at baseline had a 2.6-fold (90% confidence
interval 2.01–3.31) higher risk of seizures compared with
the reference two to six seizures. Simulations suggested
that a 400-mg/day, rather than a 200-mg/day initial target
dose for patients with seven or more seizures at baseline
could potentially result in an additional 8% of seizure-free
patients for 6 months at the last evaluated dose level.
Patients receiving lacosamide had a slightly lower dropout
risk compared with those receiving carbamazepine.
Conclusion Baseline disease severity was the most
important predictor of seizure probability. Simulations
suggest that an initial target dose [200 mg/day could
potentially benefit patients with greater disease severity.
Key Points
The present work applied time-to-event modeling to
quantify the dropout risk as well as the exposure–
response relationship between lacosamide plasma
concentration and seizure probability, in newly
diagnosed patients with focal or generalized tonic–
clonic seizures without signs of focal onset (provided
they had no history or findings suggestive of
idiopathic generalized epilepsy).
Baseline disease severity expressed as the number of
seizures in the previous 3 months was identified as a
key predictor of seizure risk in addition to the area
under the plasma concentration–time curve of
lacosamide.
Simulations suggested that an initial target dose
[200 mg/day could potentially benefit patients with
greater disease severity.
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Lacosamide (LCM) is an anti-epileptic drug (AED) that
exerts its therapeutic activity by selectively enhancing
the slow inactivation of voltage-gated sodium channels
[1]. Like that of all newer AEDs, the clinical trial pro-
gram of LCM began in the adjunctive setting, as treat-
ment for adult patients with focal epilepsy. Following
demonstration of efficacy and safety as adjunctive ther-
apy [2–4], clinical trials in the monotherapy setting were
initiated. Lacosamide was approved as monotherapy for
patients with newly diagnosed epilepsy in USA in 2014
based on the results of a historical-controlled, double-
blind, conversion-to-monotherapy trial [5]. However, for
approval in Europe, an active-controlled trial is required.
Therefore, according to European Medicines Agency
guidelines [6], a non-inferiority trial (SP0993; Clini-
calTrials.gov identifier: NCT01243177) [7] was con-
ducted with the aim of demonstrating at least a similar
benefit-risk balance for LCM compared with an
acknowledged standard AED at individually optimized
dosages using clinically relevant endpoints. The choice
of carbamazepine controlled release (CBZ-CR) as the
standard AED was based on the 2006 treatment guide-
lines of the International League Against Epilepsy [8].
Over 800 patients with newly diagnosed epilepsy were
randomized and results indicated that LCM met the
primary endpoint, based on the proportion of patients
remaining seizure free for 6 consecutive months fol-
lowing stabilization at the last evaluated dose, LCM was
non-inferior to CBZ-CR [7]. LCM was also generally
well tolerated in this patient population [7].
The aim of the present work was to identify an
exposure–response relationship under the challenging
setting of a trial design where patients move to a higher
dose level if their response is insufficient (i.e., seizures
occurring despite treatment). Given that patients could
have more than one seizure during the course of the trial,
data were analyzed using a repeated time-to-event
modeling approach. Step-wise model building was car-
ried out using data from a previous clinical trial com-
paring levetiracetam and CBZ-CR in a similar patient
population using a similar design [9]. The structural and
covariate model from this first analysis was then applied
to the new study involving LCM. The report presented
here focuses on the description and discussion of the
modeling results from that latter study. We also used
simulations to evaluate the impact of varying the dose,
according to baseline disease severity, on seizure
freedom.
2 Patients and Methods
2.1 Study Design
SP0993 (ClinicalTrials.gov identifier: NCT01243177) was
a multicenter, double-blind, double-dummy, randomized,
positive-controlled, non-inferiority trial comparing the
efficacy and safety of LCM and CBZ-CR as monotherapy
in patients with epilepsy [7]. Target dose levels were 200,
400, or 600 mg/day for LCM, and 400, 800, or
1200 mg/day for CBZ-CR, respectively (twice-daily
administration). Patients were C16 years of age and newly
diagnosed with focal or generalized tonic–clonic seizures
without signs of focal onset, provided they had no history
or clinical or electroencephalographic findings suggestive
of idiopathic generalized epilepsy. Patients with a history
or a clinical or electroencephalographic finding suggestive
of genetic generalized epilepsy were excluded [7].
The dose-escalation procedure is depicted in Fig. 1.
Patients entered a 2-week up-titration period to the first target
dose, followed by a 1-week stabilization period, a 26-week
evaluation period, and a maintenance period of 26 additional
weeks. If a seizure occurred during the evaluation period, the
dose was escalated over a 2-week period to the next level,
followed once again by a 1-week stabilization period, a
26-week evaluation period, and a 26-week maintenance per-
iod. The same process was followed in the event of a second
seizure. If patients still experienced seizures at the third dose
level, they were withdrawn from the trial.
Blood samples were collected for the determination of
LCM and CBZ plasma concentrations at the end of the up-
titration/stabilization period and at evaluation and mainte-
nance visits, as well as the early termination visit. LCM
and CBZ plasma concentrations were determined by SGS
Cephac Europe (Saint Benoit, France) using validated
liquid chromatography methods with tandem mass spec-
trometry detection. The lower limits of quantification were
0.05 and 0.25 lg/mL, respectively. The mean imprecision
(coefficient of variation) and inaccuracy (% relative error)
on quality control samples were\8 and\3% for LCM, and
\7 and\4% for CBZ, respectively.
2.2 Modeling Strategy and Software
As stated previously, step-wise model building, including
the evaluation of covariates, of the dropout and the seizure
model was carried out on a historic data set comparing
CBZ-CR with levetiracetam (N01061; ClinicalTrials.gov
identifier: NCT00150735). In a subsequent step, the
resulting final models were applied to the new dataset from
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clinical trial SP0993. Finally, all model parameters were
re-estimated on the SP0993 dataset. The turnaround time of
the SP0993 analysis was critical to meet the project time-
lines, hence this two-step approach avoiding a full model
development on SP0993 data. The parameter estimates of
the dropout and seizure model developed on N01061 data
are provided in Online Resource 1.
The analyses and simulations were performed using
NONMEM version 7.2.0 (ICON Development Solutions,
Ellicott City, Maryland, USA) [10], supplemented with the
PsN toolkit version 4.2.0 (https://uupharmacometrics.
github.io/PsN/) [11], and were further processed using R
Version 3.2.0 (https://www.r-project.org/) [12]. In the
pharmacokinetic analysis, the first-order conditional esti-
mation method with interaction was used, while the
Laplace’s method was used for the time-to-event analysis.
2.3 Pharmacokinetic Modeling
Because the available individual plasma concentration data
were rather sparse (one measurement per occasion, usually
at trough), a previously published [13] population phar-
macokinetic model for CBZ-CR was used to obtain indi-
vidual estimates of plasma clearance. Likewise, a
previously developed population pharmacokinetic model
for LCM was used for this purpose. Typical pharmacoki-
netic parameters were fixed to the historical values and
only the inter-individual variability of F and the residual
variability were estimated. The daily area under the plasma
concentration–time curve (AUC) at steady state was
derived from the empirical Bayes estimate of plasma
clearance for each patient and used as a measure of
exposure in the seizure model. A description of the phar-
macokinetic models is provided in Online Resource 2.
2.4 Dropout Modeling
Only dropout occurrences for any reason other than lack of
efficacy were taken into account for the modeling. The
probability of not having an event (i.e., no dropout) by time
t is described by the survivor function S(t), which is
determined by the hazard. A flexible empirical function
was applied as described in Frobel et al. [14], where the
hazard changes in a step-wise fashion at given breakpoints.
To avoid discontinuities in the hazard when passing a
breakpoint, often leading to numerical problems during
estimation, several sigmoidal functions were connected to
achieve some smoothness. A model with four breakpoints




BP4GAM þ tGAM ;
1 if t[BP4; 0 otherwise
FLG4 ¼ t
GAM
BP3GAM þ tGAM 
tGAM
BP4GAM þ tGAM ;
1 if t between BP3 and BP4; 0 otherwise
FLG3 ¼ t
GAM
BP2GAM þ tGAM 
tGAM
BP3GAM þ tGAM ;





BP2GAM þ tGAM ;
1 if t between BP1 and BP2; 0 otherwise
FLG1 ¼ 1 t
GAM
BP1GAM þ tGAM ;
1 if t\ BP1; 0 otherwise
Fig. 1 Design of lacosamide
(LCM) SP0993 clinical trial.
The randomization starting dose
was LCM 100 mg/day or
carbamazepine controlled
release (CBZ-CR) 200 mg/day
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h0 tð Þ ¼ k1 FLG1þ k2 FLG2þ k3 FLG3þ k4ð
FLG4þ k5 FLG5Þ
where FLG1–5 are indicator variables changing their val-
ues from 0 to 1 depending on the value of time t; a high
value of 50 was chosen for the GAM variable, to mimic a
very steep change but avoiding discontinuity. The hazard
h0(t) starts with a value of k1 until breakpoint 1 (BP1),
where it switches to k2, until time reaches BP2.
Automated stepwise covariate modeling using a forward
addition/backward deletion procedure as implemented in
PsN was applied on the N01061 dataset. The covariate
effect was added to the hazard as:
h tð Þ ¼ h0 tð Þ  expðCOVARÞ
where COVAR describes the hazard-covariate relationship.
Because this function assumes proportionality of the
hazard with respect to the covariate effect, a hazard ratio
of the covariate effect is simply: exp(COVAR). For
example:
COVAR ¼ h SEX; where SEX ¼ 1 if female; 0
if male
In this case, exp(h) is the hazard ratio of female vs.
male, with values[1 indicating a higher risk of dropout for
women.
For a continuous covariate COVAR, the relationship
was as follows (e.g., age):
COVAR ¼ h ðAGEmedian ½AGEÞ
The covariate effect relationship was considered
statistically significant when p\ 0.005 (DOFV = 7.88,
for 1 degree of freedom difference) for forward selection
and p\ 0.001 (DOFV = 10.83) for backward deletion.
The following covariates were tested: treatment (CBZ-CR,
levetiracetam, or LCM), duration of epilepsy, number of
AEDs taken before the trial, number of seizures in the
previous 3 months (NSP3M), race, geographical region,
sex, age, and body weight. The forward–backward
covariate search was performed on the N01061 dataset
but was not repeated on the SP0993 dataset in full. Any
relationship found on the N01061 dataset was maintained
for the SP0993 modeling with the coefficient re-estimated.
Only relationships pertinent to the LCM treatment were
revisited when analyzing the SP0993 data (treatment effect
on dropout).
2.5 Seizure Modeling
For the purpose of modeling, if a patient experienced
multiple seizures on one day, this was counted as a single
event and is referred to here as a seizure or seizure event.
Although roughly 30% of the patients had multiple seizure
events during the trial, a standard repeated-time-to-event
model did not satisfactorily account for the low seizure rate
overall in the population (more than 50% of the patients
had no seizure at all). Instead, an approach first presented
by Abrantes et al. [15] was successfully employed, using
two sub-models of the hazard: one for the time to the first
seizure and one for the time to the second and subsequent
seizures (time counted from the first dose):
h1stðtÞ ¼ h1st0 ðtÞ; if SCOUNT\1ðhazard for 1st seizureÞ
h2ndþðtÞ ¼ h2ndþ0 ðtÞ  expðgÞ;
if SCOUNT 1ðhazard for 2nd and subsequent seizuresÞ
where SCOUNT is a counter variable included in the
NONMEM code that starts at 0 for every new patient and
increases by one with every seizure that occurs in a patient
as the estimation proceeds through the individual data
records. The random-effect parameter g is only included in
the second hazard equation. A Weibull model was used to
describe the base hazard for h1st0 ðtÞ and h2ndþ0 ðtÞ with dif-
ferent scale (k) and shape (p) parameters (see equation
below) for each sub-model. Drug or covariate effect as
described below was explored on both hazard terms.
The effect of drug exposure (daily AUC at steady state)
on the scale parameter k was described with an exponential
function [i.e., linear with respect to ln(k)], with the AUC
centered on the typical AUC value at the first dose level for
each drug:
DE ¼ h ðAUC 104Þ; for LCM
DE ¼ h ðAUC 132Þ; for CBZ-CR
Then, the drug effect term was included in the Weibull
model:
hðtÞ ¼ k0  p ðk0  tÞp1; with k0 ¼ k expðDEÞ
Because exploratory plots indicated a very strong
relationship between the NSP3M and seizure probability,
this covariate was already included in the model during
development of the base structural model. Owing to the
skewed distribution of this variable (median 2, range
0–450), NSP3M was split into four categories:\2, 2–6,
7–50, and[50, with 2–6 being the reference category.
The process for covariate modeling was similar to that
described for the dropout model, i.e., significant
relationships found on the N01061 dataset were
maintained and coefficients re-estimated. Only the age-
relationship was revisited specifically because of the
potential clinical interested. The same covariates tested
in the dropout model were also tested in the seizure
model.
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2.6 Model Qualification
To evaluate the predictive performance of the models, visual
predictive checks (VPCs) [16] and posterior predictive checks
[17] were performed using the final model parameter esti-
mates. A simulation dataset was generated using a patient
population with the same covariates as in the dataset used for
model building. Every patient in the simulation dataset had
dummy observation records to allow for seizure or dropout
events being simulated at every day from 1 to 800.
As the simulations should mimic the original trial design
with dose escalation based on seizure events, the individual
dose and AUC were assigned to patients ‘on-the-fly’ during
the simulation. This means that the simulation code in
NONMEM (see Online Resource 4) included flag and
counter variables changing their value if a seizure (or
dropout) event was simulated at a given point in time for a
patient. If, for example, a seizure event was simulated and
the current time was within the evaluation period (days
21–203 since the start of a new dosing step), the flag for the
dose escalation was changed and at the next iteration for
this patient (next record in the simulation dataset) a higher
dose was assigned and the AUC for this patient (based on
individual pharmacokinetic parameters) was re-calculated.
If a dropout event was simulated this was also flagged
accordingly, thus records after the dropout day were fil-
tered out in the post-processing step. The simulations were
repeated 500 times and Kaplan–Meier curves comparing
observed and predicted probabilities (95% prediction
interval) were generated.
The positive predictive check focused on two trial end-
points: percentage and the Kaplan–Meier estimated propor-
tion of patients being seizure free for 6 months at the last
evaluated dose. To derive these parameters from the simu-
lated time-to-event data, only the seizure-free patients in the
evaluation period (i.e., excluding the 3-week up-titration/sta-
bilization period at the beginning of each dose step) were
counted in the post-processing step, just as in the real trial.
2.7 Simulations
Simulations were conducted to explore the potential benefit
of a higher first target dose for those patients with a high
seizure frequency at baseline. The simulation procedure
was similar to the one applied for VPCs and positive pre-
dictive checks described in the previous section. The
population characteristics for the simulations were the
same as in SP0993 (n = 443 receiving LCM). Uncertainty
was taken into account by taking the parameter vector for
each of 500 trial replicates from a bootstrap distribution.
Two scenarios were compared: scenario (A) was
essentially the same as the original design of SP0993
(‘default’ regimen): first target dose: 200 mg/day, second
target dose: 400 mg/day, third target dose: 600 mg/day. In
scenario (B), patients were stratified based on disease
severity. Patients with seven or more seizures in the pre-
vious 3 months received a first target dose of 400 mg/day,
then 600 mg/day at the second and third step (i.e., no dose
increase beyond 600 mg/day). Patients with fewer than
seven seizures received the ‘default’ regimen. Up-titration
to the target dose level during the first 3 weeks in each dose
step was taken into account in both scenarios.
3 Results
3.1 Data
In trial SP0993, 888 patients were randomized of whom
five (LCM: 2; CBZ-CR: 3) were excluded from the anal-
ysis as they withdrew their consent before receiving a dose
(n = 2), or no dosing history was available (n = 3). Valid
plasma concentration vs. time records were available from
807 patients (LCM: 407; CBZ-CR: 400) providing 3748
plasma concentrations (LCM: 1909; CBZ-CR: 1839).
About 55% of the patients in the trial did not experience
any seizures, 15% had one seizure and about 30% had two
or more seizures. A summary of the seizure events in the
trial by treatment group is provided in Online Resource 1.
In the trial, 205 of 883 (23.2%) patients discontinued
prematurely (dropout) for reasons other than lack of effi-
cacy. Of the patients who dropped out, 111 received LCM
and 94 CBZ-CR.
Summary statistics of important patient demographic
variables and the seizure count at baseline (NSP3M) are
shown in Table 1. A more complete overview of patient-
specific variables is provided in Online Resource 1.
3.2 Pharmacokinetic Modeling
Parameter estimates and goodness-of-fit plots for LCM and
CBZ are provided in Online Resource 2.
3.3 Dropout Modeling
The final dropout model consisted of four breakpoints. The
VPC shown in Fig. 2 demonstrates excellent agreement
between observed and predicted probability of dropout not
because of a lack of efficacy. Patients in the LCM group
had a slightly lower risk to drop out than those receiving
CBZ-CR; hazard ratio LCM vs. CBZ-CR was 0.871 [90%
confidence interval (CI) 0.714–1.06]. Sex was identified as
a significant covariate with a 1.27-fold (90% CI 1.04–1.55)
higher risk of dropout for women than for men across
treatments. Parameter estimates of the dropout model are
given in Table 2.
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3.4 Seizure Modeling
A significant effect of exposure on seizure probability was
identified, as indicated by the negative slope estimates for
the AUC effects of CBZ and LCM, meaning a lower hazard
for higher AUC values (Table 3). The estimates of k1 and
k2 and the shape parameters p1 and p2 refer to a typical
patient aged 41 years having experienced two to six sei-
zures in the previous 3 months and with a typical CBZ
AUC of 132 mgh/L (calculated based on the population
pharmacokinetic parameters for a 70-kg patient receiving
CBZ-CR 400 mg/day). To facilitate interpretation of the
covariate effect coefficients, hazard ratios were derived
assuming proportional hazards as shown in Table 4.
A higher NSP3M before the trial largely increased the
risk of having a seizure during the trial. A significant effect
of age was only identified for the LCM group (and for the
first seizure event), as a log-linear relationship on k1.
Testing the age effect on all patients or the CBZ group only
did not result in a significant decrease in the OFV, indi-
cating a treatment–age interaction. Older patients receiving
LCM had a somewhat lower risk of experiencing a first
seizure than younger patients.
Visual predictive checks of the Kaplan–Meier curves for
time to the first four events are presented in Fig. 2 in
Online Resource 3. While the predicted survival curves are
close to those derived from the observed data for the CBZ-
CR group, the model under-predicts the hazard in the first
2 weeks after treatment initiation (the stabilization/up-ti-
tration phase) in the LCM group. Attempts to improve the
model fit for LCM in this early phase, by including a drug
effect or NSP3M on the shape parameter or inclusion of a
higher hazard for the first 21 days, were not successful.
This early phase, however, is not essential for predicting
the clinical endpoint of interest (percentage of patients
seizure free for 6 months) because, per protocol, only
events happening during the evaluation period (i.e., after
the stabilization/up-titration) are taken into account. The
Kaplan–Meier VPC for the time to the first event in the
evaluation phase shown in Fig. 3 demonstrates that the
model was able to predict seizure probability in this rele-
vant period.
Table 1 Demographics and seizure counts at baseline
LCM CBZ-CR Total
N (%) 443 (50.2) 440 (49.8) 883 (100.0)
Age (years)
Mean (CV %) 42.0 (42.6) 41.8 (41.3) 41.9 (41.9)
Median (range) 40 (16–87) 41 (16–85) 40 (16–87)
IQR 25.5–55 26–55 26–55
Sex, n (%)
Female 200 (45.1) 209 (47.5) 409 (46.3)
Male 243 (54.9) 231 (52.5) 474 (53.7)
Number of seizures in the previous 3 months
Mean (CV %) 12.4 (319.8) 10.2 (279.1) 11.3 (305.3)
Median (range) 3 (1–450) 2 (0–300) 2 (0–450)
IQR 1–6 2–5 1–6
Number of seizures in the previous 3 months (categorical), n (%)
\2 122 (27.5) 105 (23.9) 227 (25.7)
2–6 216 (48.8) 238 (54.1) 454 (51.4)
7–50 80 (18.1) 80 (18.2) 160 (18.1)
[50 25 (5.6) 17 (3.9) 42 (4.8)
IQR interquartile range, CBZ-CR carbamazepine controlled release,
CI confidence interval, CV coefficient of variation, LCM lacosamide
LCM
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Fig. 2 Visual predictive check of dropout probability. Blue line
observed Kaplan–Meier curve of dropout not because of a lack of
efficacy in SP0993; shaded area represents the 95% prediction
interval based on 500 simulations with the updated dropout model
using SP0993 data. The drop of the curve after 400 days is owing to
most patients (the responders) exiting the trial as planned after
385 days (21 days up-titration/stabilization ? 364 days on treatment
without escalation). After this point, only a few patients remained in
the trial such that the Kaplan–Meier curve declined appreciably on
any subsequent event. CBZ carbamazepine, LCM lacosamide
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The posterior predictive check on the percentage of
patients seizure free for 6 months is shown in Fig. 4. The
predictions correspond closely to the observations in
SP0993. Additionally, the small difference between the
percentages observed in the LCM group compared with the
CBZ-CR group at the third dose step (73.6 vs. 69.7%, D
?4%) could be reproduced with the model (68.6 vs. 65.5%,
D ?3.1%). However, the difference between the two
treatments is too small to be considered of clinical
relevance.
Table 2 Parameter estimates
for the dropout model
Parameter Description Estimate 90% CIa
BP1 (day) Breakpoint 1 20 18.2–20.9
BP2 (day) D(BP2–BP1) 9.76 5.29–11.5
BP3 (day) D(BP3–BP2) 105 95.7–140
BP4 (day) D(BP4–BP3) 340 251–357
k1 (1/day)b Hazard from t = 0 to BP1 0.00205 0.0014–0.00267
k2 (1/day)b Hazard from BP1 to BP2 0.00358 0.00254–0.00601
k3 (1/day)b Hazard from BP2 to BP3 0.000946 0.000759–0.00123
k4 (1/day)b Hazard from BP3 to BP4 0.000613 0.000456–0.00074
k5 (1/day)b Hazard from BP4 to end 0.00221 0.00134–0.00358
Coeff_SEX Effect of sex = female on hazard 0.238 0.0346–0.437
HR_SEXb Hazard ratio female vs. male 1.27 1.04–1.55
Coeff_TYPE Effect of LCM on hazard -0.138 -0.333–0.0399
HR_TYPEb Hazard ratio LCM vs. CBZ-CR 0.871 0.717–1.04
BP breakpoint, CBZ-CR carbamazepine controlled release, CI confidence interval, HR hazard ratio, LCM
lacosamide
a 5th–95th percentiles of 500 bootstrap replicates
b Derived from the corresponding coefficient as: exp(x)
Table 3 Parameter estimates of the final seizure model
Parameter Description Estimate 90% CIa
k1 (1/day)b k for the time to 1st event 0.000733 0.000534 0.000957
p1 Weibull shape parameter 1st event 0.493 0.464 0.531
k2 (1/day)b k for the 2nd ? event 0.00889 0.00606 0.013
p2 Weibull shape parameter 2nd ? event 0.713 0.675 0.75
NSP3M (\2) * k1 Effect of NSP3M\2 on ln(k1) -1.12 -1.65 -0.648
NSP3M (7–50) * k1 Effect of NSP3M 7–50 on ln(k1) 1.94 1.43 2.43
NSP3M ([50) * k1 Effect of NSP3M[50 on ln(k1) 3.3 2.08 5.07
NSP3M (\2) * k2 Effect of NSP3M\2 on ln(k2) -1.37 -2.06 -0.659
NSP3M (7–50) * k2 Effect of NSP3M 7–50 on ln(k2) 1.36 0.898 1.82
NSP3M ([50) * k2 Effect of NSP3M[50 on ln(k2) 2.53 1.98 3.1
AUC_LCM * k1c Slope of AUC-ln(k1) for LCM 1st event -0.00917 -0.0164 -0.000334
AUC_CBZ * k1c Slope of AUC-ln(k1) for CBZ 1st event -0.00658 -0.015 0.00325
AUC_LCM * k2c Slope of AUC-ln(k1) for LCM 2nd ? event -0.00751 -0.00985 -0.006
AUC_CBZ * k2c Slope of AUC-ln(k1) for CBZ 2nd ? event -0.0153 -0.0183 -0.0122
AGE * k1d Slope of AGE-ln(k1) for LCM only -0.0256 -0.0449 -0.0112
IIV ln(k2) (SD) Inter-individual variability ln(k2) 2.03 1.85 2.2
AUC area under the plasma concentration–time curve over one dosing interval, CI confidence interval, CBZ carbamazepine, LCM lacosamide,
NSP3M number of seizures in the 3 months before the trial, SD standard deviation
a 5th–95th percentiles of 500 bootstrap replicates
b Parameter back-transformed to normal scale as exp(x)
c AUC centered on typical value at the first dose level (LCM 104 mgh/L; CBZ 132 mgh/L)
d AGE centered on 41 years
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An alternative endpoint in epilepsy studies is the
Kaplan–Meier estimated proportion of patients being sei-
zure free for 6 months at the last evaluated dose. In this
approach, only the number of patients at risk (i.e., not
dropped out/censored) is taken into account in the calcu-
lation of the seizure probability at each event in time.
Visual and posterior predictive checks for this endpoint are
presented in Figs. 3 and 4 in Online Resource 3 and indi-
cate a slight over-prediction of the Kaplan–Meier propor-
tion at 6 months by about 3–5%. Overall, although the
model may not be suitable for predicting seizure
probability in the first 3 weeks after the start of treatment
with LCM, it is nevertheless adequate for predicting the
clinical endpoints that by definition exclude the initial up-
titration/stabilization period.
3.5 Simulations
As shown in Table 5, in the overall LCM population, dose
individualization increased the proportion of patients
responding to treatment by about 2% at the last dose step
compared with the default dosing scheme. However, the
additional benefit was low, only about 25% of the patients
in SP0993 reported seven or fewer seizures in the previous
3 months. Focusing on this specific subset in the simula-
tions, the proportion of patients who were seizure free was
10% higher at the first dose step and 8% at the last dose




The dropout risk (not because of a lack of efficacy) was
slightly lower for patients taking LCM compared with
those taking CBZ-CR with a hazard ratio of 0.871 (90% CI
0.714–1.06; LCM vs. CBZ-CR). This may be linked to
tolerability differences between the two drugs because
fewer patients taking LCM (10.6%) than CBZ-CR (15.6%)
discontinued because of adverse events (see Baulac et al.
[7] for a detailed overview of reasons for discontinuation).
Although the CI of the hazard ratio just included 1, indi-
cating no statistical significance at the p\ 0.05 level, it
was decided to not remove the relationship from the model
because graphical diagnostics (Fig. 6 in Online Resource
3) did indicate that the relationship, albeit weak, is sup-
ported by the data.
Table 4 Derived hazard ratios for covariate effects
Covariate Hazard ratioa 90% CIb
1st seizure
NSP3M B1 vs. 2–6 0.58 0.44 0.73
NSP3M 7–50 vs. 2–6 2.60 2.02 3.31
NSP3M[50 vs. 2–6 5.09 2.79 12.20
AGE 65 vs. 41 0.74 0.59 0.88
AUCc LCM 300 vs. 100 0.40 0.20 0.97
AUC CBZ 130 vs. 210 0.77 0.55 1.14
2nd ? seizures
NSP3M B1 vs. 2–6 0.38 0.23 0.62
NSP3M 7–50 vs. 2–6 2.63 1.90 3.67
NSP3M[50 vs. 2–6 6.09 4.12 9.10
AUC LCM 300 vs. 100 0.34 0.25 0.42
AUC CBZ 130 vs. 210 0.42 0.35 0.50
AUC area under the plasma concentration–time curve in h 9 mg/L,
CBZ carbamazepine, CI confidence interval, CR controlled release,
LCM lacosamide, NSP3M number of seizures in the 3 months before
the trial
a Hazard ratios were derived as exp(coefficient 9 p), where coeffi-
cient is the estimate of the covariate effect as in Table 3 and p is the
estimate of p1 or p2. For the age and AUC effect the coefficient was
multiplied by the difference in the contrast (e.g., 65 - 41 = 24)
b 5th–95th percentiles of 500 bootstrap replicates
c Comparisons are based on the typical daily AUC values for a
patient receiving a high or low dose of LCM (200 vs. 600 mg/day) or
CBZ-CR (400 vs. 1200 mg/day)
LCM
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Fig. 3 Visual predictive check of time to first seizure in the
evaluation period. Blue line observed Kaplan–Meier curve; shaded
area represents the 95% PI based on 500 simulations. The vertical
ticks indicate dropouts in the observed data (right censoring). CBZ
carbamazepine, LCM lacosamide
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Certainly, a model that could describe the proba-
bility of dropout for each of the different reasons
(adverse events, protocol violation, withdrawal of
consent, lost to follow-up, other reasons) would have
provided a more granular description of the data.
However, it was considered that the overall low
number of dropout events did not allow for a split into
smaller categories and separate modeling, as this
would have compromised the precision of the param-
eter estimates. For this reason, the potential
relationship between exposure and dropout was not
investigated because such a relationship would only be
plausible for dropout because of adverse events.
The risk of discontinuation (not because of a lack of
efficacy) was 1.27-fold higher (90% CI 1.04–1.55) among
female compared with male patients. Of note, Kaplan–
Meier plots grouped by treatments indicated a weaker
association between sex and dropout in the LCM group
compared with the CBZ-CR group (Fig. 1 in Online
Resource 3).
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Fig. 4 Posterior predictive check for the cumulative percentage of
patients seizure free for 6 months. Gray histograms outcome of 500
replicate simulations; solid green line median of the 500 simulations;
dotted blue line observed percentages in SP0993; green area
encompasses the 95% prediction interval. CBZ carbamazepine,
LCM lacosamide
Table 5 Simulated cumulative percentage of seizure-free patients at each dose step
Subset Dosing scenarioa Percentage seizure free (90% CI)b
Dose step 1 Dose step 2 Dose step 3
All patients (A) As in SP0993 54.4 (49.4–59.1) 63.7 (59.4–68.4) 68.4 (64.1–73.4)
(B) NSP3M-based 56.7 (51.7–61.4) 66.1 (61.6–70.9) 70.2 (65.7–74.7)
Subset with NSP3M C7 (A) As in SP0993 30.5 (21.9–39.0) 41 (31.4–49.5) 49.5 (40.0–59.0)
(B) NSP3M-based 40 (28.6–52.4) 52.4 (41.0–61.9) 57.1 (46.7–65.7)
CI confidence interval, LCM lacosamide, NSP3M number of seizures in the 3 months before the trial
a Default dosing scheme of LCM as in SP0993 is compared with a regimen with a higher initial target dose for patients with NSP3M C7
b 5th–95th percentiles of 500 bootstrap replicates
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4.2 Seizure Modeling
The seizure model aimed at demonstrating and quantifying
the impact of drug exposure on the probability of seizure
events. The trial design did not allow for a straightforward
comparison of e.g., median time-to-seizure per dose group.
In fact, the response-dependent dose escalation inevitably
led to confounding of dose (or exposure) and pharmaco-
dynamic effect (i.e., sensitivity to the drug, responsive-
ness), meaning that patients who responded poorly or not at
all received the highest dose. Although the design limita-
tions are recognized [18, 19], they do reflect clinical
practice. Non-linear mixed-effects modeling can, to some
extent, overcome this issue. In a seminal article about the
design of dose-ranging studies [20], Sheiner et al. used the
example of a blood pressure-lowering drug to explain how
unbiased estimates of the dose–response relationship can
be obtained in a dose-escalation trial by analyzing the data
with a parametric pharmacokinetic/pharmacodynamic
model. Alternative analysis methods (analysis of variance,
analysis of covariance) based on group comparisons,
however, fail in this context.
Nevertheless, the absence of a placebo group (for ethical
reasons) and the relatively narrow dose range in the current
trial prevented exploration of more pharmacologically
plausible models, such as the (sigmoid) Emax model [at-
tempts resulted in unstable models, sensitive to changes in
initial estimates]. An assessment of the relative potency of
the drugs investigated is also very limited for similar rea-
sons (absence of a common anchor point). Despite these
shortcomings, it could be shown that AUC is an important
predictor of efficacy.
To appropriately handle the AUC-hazard relationship
across the different dose-escalation steps as described
before, it was necessary to account for the fact that many
patients had more than one seizure event during the course
of the trial. Therefore, a repeated-time-to-event framework
was used. However, owing to the low overall seizure rate—
approximately 50% of the patients reported no seizure—
there was a severe imbalance in the distribution of the
between patient variability on the hazard [those with no
event share the same (low) hazard, the rest of the patients
are more normally distributed]. To account for this data
feature, the hazards for the first and subsequent seizures
were handled separately by two sub-models (Fig. 5 in
Online Resource 3 illustrates the hazard curves for the two
sub-models). Considering that only the subset of patients
with more than one seizure informed the parameters of the
second sub-model, the covariate relationships can differ
between the two terms. This has also been observed by
Abrantes et al., who applied this approach for patients with
epilepsy during a short-term hospital stay [15]. A downside
of this approach is that model parameters are not directly
interpretable in terms of their impact on the clinical end-
point in a quantitative manner and simulations need to be
performed to assess the influence of, for example, covari-
ates on the percentages of patients seizure free for
6 months.
4.3 Simulations
During development of the seizure model, the NS3PM was
identified as having important predictive value. Therefore,
potential clinical implications in terms of an optimized
dosing strategy for LCM based on baseline disease severity
was explored further. A simulation scenario was set up
where a higher dose was given to patients with a more
severe disease state (seven or more seizures in the previous
3 months). In fact, the overall percentage of patients sei-
zure free for 6 months at the last evaluated dose would be
slightly higher (by approximately 2%) if such a treatment
schedule with a priori dose individualization would be
applied to a patient population similar to the one studied in
SP0993 (Table 5). The benefit may appear rather small
overall. However, focusing on the subset of patients with
seven or more seizures in the previous 3 months, it
becomes clear that indeed this subgroup could benefit from
a higher initial LCM target dose. For example, the differ-
ence in response rate between patients receiving a higher
initial target dose (400 mg/day) and those receiving a
lower initial target dose (200 mg/day) was simulated to be
about 10% at the first dose step and 8% at the last dose
step. A limitation of this simulation is that it is based
only on an efficacy model, while in clinical practice, tol-
erability is also taken into account when selecting titration
schedule and initial target dose. Nevertheless, the simula-
tions provide a basis for exploring such a priori individu-
alization strategies in a clinical context where an
appropriate benefit-risk assessment can be made.
Currently, it is common practice in the treatment of
patients with epilepsy to adapt the dose of the drug based
on response and tolerability (i.e., dose increase if seizures
occur, dose reduction in the case of adverse events). Tar-
geting a maintenance dose (following up-titration) that is
closer to the individual optimal dose may have the poten-
tial to save the patient some iterations in this empirical
dose-finding process. Additional studies to validate this
approach should specifically investigate potential tolera-
bility issues associated with higher doses.
5 Conclusions
A repeated time-to-event model was successfully applied
to quantify the exposure–response relationship of LCM
(and CBZ-CR) on the probability of seizures in patients
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aged C16 years newly diagnosed with focal or generalized
tonic–clonic seizures without signs of focal onset (provided
they had no history or findings suggestive of idiopathic
generalized epilepsy). Baseline disease severity expressed
as NSP3M was found to be the most important predictor of
seizure probability. Simulations suggest that patients with
seven or more seizures in the previous 3 months would
benefit from a dosing regimen aiming at a higher target
maintenance dose. Further clinical research is needed to
confirm these findings and to ensure that tolerability is not
compromised.
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